Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) will present new findings from its ongoing phase II clinical trial at the American Association for Cancer Research Immuno-Oncology (AACR IO) conference in Los Angeles from 23-26 February.
The data will highlight how its experimental melanoma vaccine, SCIB1, is working in combination with two widely used cancer drugs, nivolumab and ipilimumab.
SCIB1 is a DNA-based cancer vaccine designed to train the immune system to recognise and destroy melanoma cells. The study, known as SCOPE, is testing SCIB1 alongside checkpoint inhibitors—drugs that help the immune system attack cancer more effectively.
Early results from 25 patients show promising signs, with 84% seeing their disease controlled, 80% remaining progression-free, and 20% experiencing a complete response, meaning no signs of cancer were detected.
The new data, to be presented at the AACR IO conference, provides deeper insight into how SCIB1 activates the body’s immune T cells to fight melanoma. Scancell believes these findings will support further development of the vaccine as a new treatment option for advanced melanoma.
"Presenting data showing vaccine-specific T cell responses at AACR IO is an important validation of SCIB1 efficacy in advanced melanoma," said Scancell CEO Phil L'Huillier.
"This data supports the latest findings from the phase II Scope trial, evaluating SCIB1 in combination with CPIs. We look forward to sharing the latest insights with leading industry experts at AACR IO."